Overview Rollover Study Of Lapatinib In Cancer Patients Status: Completed Trial end date: 2009-05-05 Target enrollment: Participant gender: Summary The EGF19060 study is a rollover study to evaluate the long term safety of lapatinib and to provide lapatinib to patients who had a positive response in previous lapatinib studies until lapatinib is available pending FDA approval. Phase: Phase 1 Details Lead Sponsor: GlaxoSmithKlineTreatments: Lapatinib